BPT-143: a fully synthetic alpha-dead IL-2 with a best-in-class preclinical pharmacodynamic and efficacy profile supporting first-in-human clinical development

BPT-143 - Bright Peak Therap

Proleukin (aldesleukin) - Clinigen, Novartis, Prometheus

Jean-Philippe Carralot, Rubén Alvarez Sanchez, Matilde Arévalo Ruiz, Magali Muller, Vijaya R. Pattabiraman, Bertolt Kreft

Mar 9, 2022